02410.HK
TYK Medicines, Inc
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.26
−1.51%Sep 20, 2026, 11:33 UTC
Tongyuantang Pharmaceutical (02410) announced that its subscription agreement to issue 63.2227 million H shares to Qilu lapsed on September 20, 2026 after the revised long-stop date passed without the conditions being fulfilled or waived.
Source:Sep 9, 2026, 01:09 UTC
Tongyuankang Medical's chairman Wu Yusheng purchased shares in the open market and plans to increase holdings by up to 2 million yuan.
Source:Aug 27, 2026, 14:31 UTC
TYK Medicines announced that its self-developed innovative drug TY-9591 tablets (deuterated almonertinib mesylate) received conditional marketing approval from China's National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutation and central nervous system metastases.
Source:Aug 17, 2026, 14:08 UTC
Tongyuan Kang Medical reported interim results for the six months ended June 2026, with a narrowed loss of 24.9 million RMB compared to a loss of 112 million RMB in the same period last year, no revenue generated, and no dividend declared.
Source:Jul 22, 2026, 09:21 UTC
Huiyu Pharmaceutical and TYK Medicines have filed mutual lawsuits over the product agreement for TY-9591.
Source: